Journal of Neural Transmission

, Volume 118, Issue 12, pp 1691–1702 | Cite as

Continuous drug delivery in early- and late-stage Parkinson’s disease as a strategy for avoiding dyskinesia induction and expression

Movement Disorders - Review article

Abstract

The treatment of the motor symptoms of Parkinson’s disease (PD) is dependent on the use of dopamine replacement therapy in the form of l-dopa and dopamine agonist drugs. However, the development of dyskinesia (chorea, dystonia, athetosis) can become treatment limiting. The initiation of dyskinesia involves a priming process dependent on the presence of nigral dopaminergic cell loss leading to alterations in basal ganglia function that underlie the expression of involuntary movements following the administration of each drug dose. Once established, dyskinesia is difficult to control and it is even more difficult to reverse the priming process. Dyskinesia is more commonly induced by l-dopa than by dopamine agonist drugs. This has been associated with the short duration of l-dopa causing pulsatile stimulation of postsynaptic dopamine receptors compared to the longer acting dopamine agonists that cause more continuous stimulation. As a result, the concept of continuous dopaminergic stimulation (CDS) has arisen and has come to dominate the strategy for treatment of early PD. However, CDS has flaws that have led to the general acceptance that continuous drug delivery (CDD) is key to the successful treatment of PD. Studies in both experimental models of PD and in clinical trials have shown CDD to improve efficacy, but reduce dyskinesia induction, and to reverse established involuntary movements. Two key clinical strategies currently address the concept of CDD: (1) in early-, mid- and late-stage PD, transdermal administration of rotigotine provides 24 h of drug delivery; (2) in late-stage PD, the constant intraduodenal administration of l-dopa is utilized to improve control of motor symptoms and to diminish established dyskinesia. This review examines the rationale for CDD and explores the clinical benefit of using such a strategy for the treatment of patients with PD.

Keywords

CDS CDD L-dopa Rotigotine Duodopa Dyskinesia 

References

  1. Antonini A, Isaias IU, Canesi M et al (2007) Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord 22:1145–1149PubMedCrossRefGoogle Scholar
  2. Antonini A, Mancini F, Canesi M et al (2008) Duodenal levodopa infusion improves quality of life in advanced Parkinson’s disease. Neurodegener Disord 5:244–246CrossRefGoogle Scholar
  3. Apokyn (apomorphine hydrochloride injection) prescribing information (2004)Vernalis Pharmaceuticals Incorporated, MorristownGoogle Scholar
  4. Bamford NS, Robinson S, Palmiter RD et al (2004) Dopamine modulates release from corticostriatal terminals. J Neurosci 24:9541–9552PubMedCrossRefGoogle Scholar
  5. Baronti F, Mouradian MM, Davis TL et al (1992) Continuous lisuride effects on central dopaminergic mechanisms in Parkinson’s disease. Ann Neurol 32:776–781PubMedCrossRefGoogle Scholar
  6. Belluzzi JD, Domino EF, May JM et al (1994) N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson’s disease. Mov Disord 9:147–154Google Scholar
  7. Bibbiani F, Costantini LC, Patel R et al (2005) Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 192:73–78PubMedCrossRefGoogle Scholar
  8. Blanchet PJ, Calon F, Martel JC et al (1995) Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 272:854–859PubMedGoogle Scholar
  9. Boroojerdi B, Wolff HM, Braun M, Scheller DK (2010) Rotigotine transdermal patch for the treatment of Parkinson’s disease and restless legs syndrome. Drugs Today (Barc) 46(7):483–505CrossRefGoogle Scholar
  10. Braun M, Cawello W, Poole K et al (2005) Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson’s disease. Eur J Neurol 12(S2):96Google Scholar
  11. Cawello W, Braun M, Boekens H (2009) Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 37:2055–2060PubMedCrossRefGoogle Scholar
  12. Chase TN (1998) The significance of continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Drugs 55(S1):1–9PubMedCrossRefGoogle Scholar
  13. Colzi A, Turner K, Lees AJ (1998) Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease. J Neurol Neurosurg Psychiatry 64:573–576PubMedCrossRefGoogle Scholar
  14. de la Fuente-Fernandez R, Sossi V et al (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: implications for dyskinesias. Brain 127:2747–2754PubMedCrossRefGoogle Scholar
  15. den Daas I, Tepper PG, Rollema H et al (1990) Transdermal administration of the dopamine agonist N-0437 and seven ester prodrugs: comparison with oral administration in the 6-OHDA turning model. Naunyn Schmiedebergs Arch Pharmacol 342: 655–699Google Scholar
  16. Devos D, French DUODOPA Study Group (2009) Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord 24:993–1000PubMedCrossRefGoogle Scholar
  17. Eggert K, Schrader C, Hahn M et al (2008) Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 31:151–166PubMedCrossRefGoogle Scholar
  18. Giladi N, Boroojerdi B, Korczyn AD et al (2007) Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22:2398–2404PubMedCrossRefGoogle Scholar
  19. Giladi N, Jankovic J, Watts RL et al (2010) Effects of Long-Term Treatment With Rotigotine Transdermal Patch on Dyskinesias in Early-stage Parkinson’s Disease (PD): results from Two Open-Label Extension Trials. European Federation of Neurological Societies—14th Congress, Eur J Neurol 17(suppl 3):121, abs. P1113Google Scholar
  20. Goerendt IK, Messa C, Lawrence AD (2003) Dopamine release during sequential finger movements in health and Parkinson’s disease: a PET study. Brain 126:312–325PubMedCrossRefGoogle Scholar
  21. Goggi JL, Sardini A, Egerton A et al (2007) Agonist-dependent internalization of D2 receptors: imaging quantification by confocal microscopy. Synapse 61:231–241PubMedCrossRefGoogle Scholar
  22. Goto Y, Otani S, Grace AA (2007) The Yin and Yang of dopamine release: a new perspective. Neuropharmacology 53:583–587PubMedCrossRefGoogle Scholar
  23. Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41:1–24PubMedCrossRefGoogle Scholar
  24. Grace AA (2008) Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy. Mov Disord 23(S3):560–569CrossRefGoogle Scholar
  25. Holloway RG, Shoulson I, Fahn S, Parkinson Study Group et al (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044–1053PubMedCrossRefGoogle Scholar
  26. Honig H, Antonini A, Martinez-Martin P et al (2009) Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468–1474PubMedCrossRefGoogle Scholar
  27. Isacson D, Bingefors K, Kristiansen IS et al (2008) Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurol Scand 118:379–386PubMedCrossRefGoogle Scholar
  28. Jackson MJ, Smith LA, Al-Barghouthy G et al (2007) Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Exp Neurol 204:162–170PubMedCrossRefGoogle Scholar
  29. Jenner P (2003) The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson’s disease. Parkinsonism Relat Disord 9:131–137PubMedCrossRefGoogle Scholar
  30. Jenner P (2008) Preventing and controlling dyskinesia in Parkinson’s disease—a view of current knowledge and future opportunities. Mov Disord 23(S3):585–598CrossRefGoogle Scholar
  31. Jenner P (2009) From the MPTP-treated primate to the treatment of motor complications in Parkinson’s disease. Parkinsonism Relat Disord 15(S4):18CrossRefGoogle Scholar
  32. Jennings DL, Tabamo R, Seibyl JP et al (2007) InSPECT: investigating the effect of short-term treatment with pramipexole or l-dopa on [123I] β-CIT and SPECT imaging. Mov Disord 22(S16):143–144Google Scholar
  33. Juncos JL, Engber TM, Raisman R et al (1989) Continuous and intermittent l-dopa differentially affect basal ganglia function. Ann Neurol 25:473–478PubMedCrossRefGoogle Scholar
  34. Karoum F, Freed WJ, Chuang LW (1988) d-dopa and l-dopa similarly elevate brain dopamine and produce turning behavior in rats. Brain Res 440:190–194PubMedCrossRefGoogle Scholar
  35. Katzenschlager R, Hughes A, Evans A et al (2005) Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov Disord 20:151–157PubMedCrossRefGoogle Scholar
  36. Kehr J, Hu XJ, Goiny M, Scheller DK (2007) Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation. J Neural Transm 114:1027–1031PubMedCrossRefGoogle Scholar
  37. Kristiansen IS, Bingefors K, Nyholm D et al (2009) Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson’s disease in Sweden: an exploratory study. Appl Health Econ Health Policy 7:167–180PubMedGoogle Scholar
  38. Kurlan R, Nutt JG, Woodward WR (1988) Duodenal and gastric delivery of l-dopa in parkinsonism. Ann Neurol 23:589–595PubMedCrossRefGoogle Scholar
  39. Kurth MC, Tetrud JW, Tanner CM et al (1993) Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson’s disease patients with ‘on-off’ fluctuations. Neurology 43:1698–1703PubMedGoogle Scholar
  40. Kvernmo T, Hartter S, Burger E (2006) A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 28:1065–1078PubMedCrossRefGoogle Scholar
  41. LeWitt PA, Lyons KE, Pahwa R (2007) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68(16):1262–1267PubMedCrossRefGoogle Scholar
  42. Lindgren HS, Andersson DR, Lagerkvist S et al (2010) l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson’s disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 112:1465–1476PubMedCrossRefGoogle Scholar
  43. Loeschmann PA, Chong PN, Nomoto M et al (1989) Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437. Eur J Pharmacol 166:373–380CrossRefGoogle Scholar
  44. Loeschmann PA, Smith LA, Lange KW et al (1992) Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets. Psychopharmacology (Berl) 109:49–56Google Scholar
  45. Malik M, Andreas JO, Hnatkova K et al (2008) Thorough QT/QTc study in patients with advanced Parkinson’s disease: cardiac safety of rotigotine. Clin Pharmacol Ther 84:595–603PubMedCrossRefGoogle Scholar
  46. Manson AJ, Hanagasi H, Turner K et al (2001) Intravenous apomorphine therapy in Parkinson’s disease: clinical and pharmacokinetic observations. Brain 124:331–340PubMedCrossRefGoogle Scholar
  47. Maratos EC, Jackson MJ, Pearce RK et al (2001) Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). Mov Disord 16:631–641PubMedCrossRefGoogle Scholar
  48. Maratos EC, Jackson MJ, Pearce RK et al (2003) Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than l-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Exp Neurol 179:90–102PubMedCrossRefGoogle Scholar
  49. Marion MH, Stocchi F, Quinn NP et al (1986) Repeated levodopa infusions in fluctuating Parkinson’s disease: clinical and pharmacokinetic data. Clin Neuropharmacol 9:165–181PubMedCrossRefGoogle Scholar
  50. Miller DW, Abercrombie ED (1999) Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous l-DOPA: studies in intact and 6-hydroxydopamine-treated rats. J Neurochem 72:1516–1522PubMedCrossRefGoogle Scholar
  51. Morissette M, Goulet M, Soghomonian JJ et al (1997) Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with l-DOPA therapy. Brain Res Mol Brain Res 49:55–62PubMedCrossRefGoogle Scholar
  52. Mouradian MM, Heuser IJ, Baronti F et al (1990) Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson’s disease. Ann Neurol 27:18123CrossRefGoogle Scholar
  53. Muenter MD, Tyce GM (1971) l-dopa therapy of Parkinson’s disease: plasma l-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 46:231–239PubMedGoogle Scholar
  54. Nilsson D, Hansson LE, Johansson K et al (1998) Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson’s disease. Acta Neurol Scand 97:175–183PubMedCrossRefGoogle Scholar
  55. Nilsson D, Nyholm D, Aquilonius SM (2001) Duodenal levodopa infusion in Parkinson’s disease—long-term experience. Acta Neurol Scand 104:343–348PubMedCrossRefGoogle Scholar
  56. Nutt JG, Carter JH, Lea ES et al (1997) Motor fluctuations during continuous levodopa infusions in patients with Parkinson’s disease. Mov Disord 12:285–292PubMedCrossRefGoogle Scholar
  57. Nutt JG, Obeso JA, Stocchi F (2000) Continuous dopamine-receptor stimulation in advanced Parkinson’s disease. Trends Neurosci 23(10 S):109–115CrossRefGoogle Scholar
  58. Nyholm D, Askmark H, Gomes-Trolin C et al (2003) Optimizing pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 26:156–163PubMedCrossRefGoogle Scholar
  59. Nyholm D, Nilsson Remahl AI, Dizdar N (2005) Duodenal l-dopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64:216–223PubMedCrossRefGoogle Scholar
  60. Nyholm D, Lewander T, Johansson A et al (2008) Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008(31):63–73CrossRefGoogle Scholar
  61. Oertel WH, Wolters E, Sampaio C et al (2006) Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord 21:343–353PubMedCrossRefGoogle Scholar
  62. Olanow CW, Stern MB, Sethi K (2009) The scientific and clinical basis for the treatment of Parkinson disease. Neurology 72:1–136CrossRefGoogle Scholar
  63. Papathanou M, Kooyman E, van der Laan R et al (2009) A preliminary pharmacokinetic study comparing l-DOPA and duodopa in adult rats. Poster 2.193, World Federation of Neurology XIX Congress, Miami Beach, FloridaGoogle Scholar
  64. Papathanou M, van der Laan R, Jenner P et al (2011) Both pulsatile and continuous administration of l-dopa prime for abnormal involuntary movements in 6-OHDA-lesioned rats [in revision]Google Scholar
  65. Parkinson Study Group (2003) A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol 60:1721–1728CrossRefGoogle Scholar
  66. Pearce RK, Banerji T, Jenner P et al (1998) De novo administration of ropinirole and bromocriptine induces less dyskinesia than l-dopa in the MPTP-treated marmoset. Mov Disord 13:234–241PubMedCrossRefGoogle Scholar
  67. Picconi B, Centonze D, Hakansson K et al (2003) Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat Neurosci 6:501–506PubMedGoogle Scholar
  68. Poewe WH, Rascol O, Quinn N et al (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6(6):513–520PubMedCrossRefGoogle Scholar
  69. Quinn N (2001) A multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of rotigotine constant delivery system (CDS) in patients with advanced Parkinson’s disease. Parkinsonism Rel Disord 7(S1):S66Google Scholar
  70. Quinn N, Parkes JD, Marsden CD (1984) Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 34:1131–1136PubMedGoogle Scholar
  71. Rao SS, Hofmann LA, Shakil A (2006) Parkinson’s disease: diagnosis and treatment. Am Fam Phys 74(12):2046–2054Google Scholar
  72. Rascol O, Brooks DJ, Korczyn AD et al (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484–1491PubMedCrossRefGoogle Scholar
  73. Rascol O, Brooks DJ, Korczyn AD et al (2006) Development of dyskinesias in a 5-year trial of ropinirole and l-dopa. Mov Disord 21:1844–1850PubMedCrossRefGoogle Scholar
  74. Rinne UK, Bracco F, Chouza C et al (1998) Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55(S1):23–30PubMedCrossRefGoogle Scholar
  75. Rye DB (2004) The two faces of Eve: dopamine’s modulation of wakefulness and sleep. Neurology 63(8,S3):2–7Google Scholar
  76. Sage JI, Trooskin S, Sonsalla PK et al (1988) Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 24:87–89PubMedCrossRefGoogle Scholar
  77. Schapira AH, Olanow CW (2004) Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291:358–364PubMedCrossRefGoogle Scholar
  78. Scheller D, Ullmer C, Berkels R et al (2009) The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn Schmiedebergs Arch Pharmacol 379:73–86PubMedCrossRefGoogle Scholar
  79. Schmidt WJ, Lebsanft H, Heindl M et al (2008) Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. J Neural Transm 115:1385–1392PubMedCrossRefGoogle Scholar
  80. Schuh LA, Bennett JP Jr (1993) Suppression of dyskinesias in advanced Parkinson’s disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson’s disease. Neurology 43:1545–1550PubMedGoogle Scholar
  81. Schultz W (1994) Behavior-related activity of primate dopamine neurons. Rev Neurol (Paris) 150:634–639Google Scholar
  82. Shen W, Flajolet M, Greengard P et al (2008) Dichotomous dopaminergic control of striatal synaptic plasticity. Science 321:848–851PubMedCrossRefGoogle Scholar
  83. Stocchi F (2008) Use of apomorphine in Parkinson’s disease. Neurol Sci 29:S383–386Google Scholar
  84. Stocchi F, Ruggieri S, Vacca L et al (2002) Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease. Brain 125:2058–2066PubMedCrossRefGoogle Scholar
  85. Stocchi F, Vacca L, Ruggieri S et al (2005) Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 62:905–910PubMedCrossRefGoogle Scholar
  86. Stocchi F, Rascol O, Kieburtz K et al (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68:18–27PubMedCrossRefGoogle Scholar
  87. Stockwell KA, Scheller D, Rose S et al (2009) Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. Exp Neurol 219:533–542PubMedCrossRefGoogle Scholar
  88. Stockwell KA, Scheller DK, Smith LA et al (2010) Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or l-DOPA in MPTP-treated common marmosets. Exp Neurol 221:79–85PubMedCrossRefGoogle Scholar
  89. Van der Weide J, De Vries JB, Tepper PG et al (1986) Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734. Eur J Pharmacol 125:273–282PubMedCrossRefGoogle Scholar
  90. Van der Weide J, Tendijck ME, Tepper PG et al (1988) The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and postsynaptic dopamine receptors. Eur J Pharmacol 146:319–326PubMedCrossRefGoogle Scholar
  91. Venton BJ, Zhang H, Garris PA et al (2003) Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing. J Neurochem 87:1284–1295PubMedCrossRefGoogle Scholar
  92. Watts RL, Jankovic J, Waters C et al (2007) Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68:272–276PubMedCrossRefGoogle Scholar
  93. Watts RL, Pahwa R, Lyons KE et al (2009) Long-term safety of rotigotine transdermal patch in early-stage Parkinson’s disease: results from 4 years. Mov Disord 24(S1):286Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • P. Jenner
    • 1
  • A. C. McCreary
    • 2
  • D. K. A. Scheller
    • 3
  1. 1.Neurodegenerative Disease Research Group, Institute of Pharmaceutical Sciences, School of Biomedical SciencesKing’s CollegeLondonUK
  2. 2.Brains On-LineGroningenThe Netherlands
  3. 3.UCB PharmaBrusselsBelgium

Personalised recommendations